Novozymes completed the acquisition of Chr. Hansen for $12.3bn.

Novozymes, a Danish food ingredients and enzymes maker, completed the acquisition of Chr. Hansen, a bioscience company, for $12.3bn. "We have successfully combined Novozymes and Chr. Hansen and today we come together as one leading global biosolutions partner. Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10k colleagues, we will unlock the limitless potential of biosolutions," Ester Baiget, Novonesis President and CEO.